CD20 antibody–based combination therapy may reduces the adverse prognostic impact of M-protein positivity in marginal zone lymphoma

IF 0.8 Q4 HEMATOLOGY

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-10-09 DOI:10.1016/j.lrr.2026.100616

Yajun Zhang, Wanqian Hu, Ying Fang, Bo Zheng, Yi Zhang, Wenda Chen, Rong Li

{"title":"CD20 antibody–based combination therapy may reduces the adverse prognostic impact of M-protein positivity in marginal zone lymphoma","authors":"Yajun Zhang, Wanqian Hu, Ying Fang, Bo Zheng, Yi Zhang, Wenda Chen, Rong Li","doi":"10.1016/j.lrr.2026.100616","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Monoclonal M-protein is frequently detected in marginal zone lymphoma (MZL) and has been historically associated with adverse clinical features. Its prognostic value in the era of modern immunotherapy remains unclear.</div></div><div><h3>Patients and methods</h3><div>We retrospectively analyzed 43 patients with MZL, comparing clinical characteristics, treatments, and outcomes between patients with and without M-protein. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier analysis, and prognostic factors were evaluated by Cox regression.</div></div><div><h3>Results</h3><div>M-protein was detected in 39.5% of patients and was associated with higher tumor burden, worse performance status, and elevated inflammatory and biochemical markers. However, no significant differences in PFS or OS were observed between groups, and M-protein was not an independent prognostic factor. Most patients received contemporary CD20 antibody–based combination therapies.</div></div><div><h3>Conclusion</h3><div>In the setting of modern treatments, M-protein positivity may not confer an adverse prognostic impact in MZL.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"26 ","pages":"Article 100616"},"PeriodicalIF":0.8000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048926000567","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/9 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Monoclonal M-protein is frequently detected in marginal zone lymphoma (MZL) and has been historically associated with adverse clinical features. Its prognostic value in the era of modern immunotherapy remains unclear.

Patients and methods

We retrospectively analyzed 43 patients with MZL, comparing clinical characteristics, treatments, and outcomes between patients with and without M-protein. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier analysis, and prognostic factors were evaluated by Cox regression.

Results

M-protein was detected in 39.5% of patients and was associated with higher tumor burden, worse performance status, and elevated inflammatory and biochemical markers. However, no significant differences in PFS or OS were observed between groups, and M-protein was not an independent prognostic factor. Most patients received contemporary CD20 antibody–based combination therapies.

Conclusion

In the setting of modern treatments, M-protein positivity may not confer an adverse prognostic impact in MZL.

查看原文本刊更多论文

CD20抗体联合治疗可降低m蛋白阳性对边缘区淋巴瘤预后的不良影响

背景：单克隆m蛋白经常在边缘区淋巴瘤（MZL）中检测到，并且历来与不良临床特征相关。其在现代免疫治疗时代的预后价值尚不清楚。患者和方法我们回顾性分析了43例MZL患者，比较了携带和不携带m蛋白患者的临床特征、治疗方法和结局。采用Kaplan-Meier分析评估无进展生存期（PFS）和总生存期（OS），采用Cox回归评估预后因素。结果39.5%的患者检测到sm -蛋白，与肿瘤负担加重、运动状态恶化、炎症和生化指标升高相关。然而，两组间PFS和OS没有显著差异，m蛋白也不是独立的预后因素。大多数患者接受了基于CD20抗体的当代联合治疗。结论在现代治疗的背景下，m蛋白阳性可能不会对MZL患者的预后产生不良影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊